EPCT-24 THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

BACKGROUND: Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS: Patients (n=18) received autologous tumor antigen-associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Melanie, Fortiz, Maria, Wang, Lu, Lang, Haili, Datar, Anushree, Reynolds, Emily, Terpilowski, Madeleine, Geiger, Ashley, Lazarski, Chris, Tanna, Jay, Pitino, Adriana, Zhang, Nan, Hoq, Fahmida, Hanley, Patrick, Cruz, C Russell, Kilburn, Lindsay, Packer, Roger, Rood, Brian, Bollard, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Translational/Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168094/
http://dx.doi.org/10.1093/neuonc/noab090.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168094/
http://dx.doi.org/10.1093/neuonc/noab090.210

Ejemplares similares